Addex Therapeutics (FRA:APE1) Payments of Debt: €-0.01 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.88
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics Payments of Debt?

Addex Therapeutics FRA:APE1 -0.81% 7 Payments of Debt is €-0.01 Mil as of Mar. 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100. The stock has 6 warning signs investors should review.

Addex Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was €-0.00 Mil.

Addex Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01 Mil.

Addex Therapeutics Payments of Debt Related Terms

Addex Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Payments of Debt Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 -0.29 -0.30 -0.08 -0.01

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 -0.00
FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-0.01 Mil mean?
Addex Therapeutics (FRA:APE1) has a Payments of Debt of €-0.01 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Payments of Debt too high?
Addex Therapeutics' current Payments of Debt is €-0.01 Mil. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Payments of Debt compare to VRTX and REGN?
Addex Therapeutics' Payments of Debt of €-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Payments of Debt is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Payments of Debt of €-0.01 Mil. The current Payments of Debt is €-0.01 Mil. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Payments of Debt is €-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.88
Price